Piper Sandler Reiterates Overweight Rating on Sutro Biopharma (STRO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
TD Cowen Reiterates Buy Rating on Sutro Biopharma (STRO)
September 16, 2024 9:11 AM EDTTD Cowen analyst Tara Bancroft reiterated a Buy rating on Sutro Biopharma (NASDAQ: STRO).
The analyst commented, "Luvelta+bev's 35% ORR in an unselected population and multiple doses is impressive on its own given that Elahere+bev had a 44% ORR in higher... More
